Lundbeck's Vyepti Launch In US Disappoints In First Half
But 2020 EBIT Guidance Revised Upwards
The coronavirus pandemic held back sales of Lundbeck’s newest product, Vyepti, in the US during the first half, but the company spent less than expected on SG&A because of COVID-19, and increased investments in marketing infrastructure and restructuring R&D.
